trial for SGR-2921, which targets KRAS mutant tumors, is expected to be completed by the end of this year. Schrodinger\’s stock has had a volatile year, currently down 18%, but analysts are bullish on its long-term prospects. Goldman Sachs analyst Graig Suvannavejh wrote in a note in June that he expects Schrodinger to start to gain more recognition as its internal pipeline matures. The company has a unique position in the market, he said, with its physics-based platform potentially offering a more rational approach to drug discovery. The stock has an average price target of $83.50, according to FactSet, well above where it is currently trading. With its diverse portfolio of drug candidates and collaborations, Schrodinger is well-positioned to capitalize on the growing interest in AI-driven drug discovery. While there are risks associated with investing in companies at the forefront of AI in drug discovery, the potential rewards for successful companies could be significant. As these companies continue to innovate and develop new technologies, investors will be closely watching for clinical readouts and updates on their progress. The intersection of AI and drug discovery holds immense promise for revolutionizing the pharmaceutical industry, and those who are able to navigate the challenges and capitalize on the opportunities presented by this rapidly evolving field stand to benefit greatly in the years to come.\”
